Ebola Vaccine — Phase 1 | NEJM Clinician

A chimpanzee adenovirus vector vaccine was safe and induced an immune response in a phase 1 open-label clinical trial.

Several candidate vaccines aimed at safely and efficaciously preventing Ebola virus disease are being explored. On the heels of nonhuman primate infection-model studies, researchers have conducted a phase 1 clinical trial of a replication-defective recombinant chimpanzee adenovirus type 3–vectored Ebola vaccine.

Twenty healthy adults from the Washington, DC, area received a single intramuscular dose of vaccine that included either 2×10¹⁰ particle units (group 1) or 2×10¹¹ particle units (group 2). Safety monitoring and evaluation of immunogenic responses were conducted during the first 4 weeks after vaccination.

No serious adverse events occurred in either group. Two group 2 participants developed fever within 24 hours after vaccination, and …

Reviewing Author

Larry M. Baddour, MD

Disclosures

RoyaltiesUpToDate, Inc. (Authorship duties)

Larry M. Baddour, MD

Disclosures

RoyaltiesUpToDate, Inc. (Authorship duties)

Ebola Vaccine — Phase 1

Topics

Reviewing Author